I agree. My gut feel is that the way they are modifying the anthracycline to reduce cardiotoxicity also reduces the anti-cancer effect. It simply taking away the cytotoxic effects and thus reducing cardiotoxicity.
The ROS production aids the anti-cancer effect and thus preventing this reduces efficacy. Bisantrene has a magic wand that has (i) low cardiotoxicity (ii) protects against cardiotoxicity of other anthracyclines, and (iii) increases anti-cancer effect by way of synergy.
Cardioprotection thread, page-11
-
- There are more pages in this discussion • 895 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
